Literature DB >> 17005844

Standardization of an experimental murine model of invasive pulmonary aspergillosis.

Donald C Sheppard1, John R Graybill, Laura K Najvar, Lisa Y Chiang, Thomas Doedt, William R Kirkpatrick, Rosie Bocanegra, Ana C Vallor, Thomas F Patterson, Scott G Filler.   

Abstract

Evaluating new therapeutic agents for invasive aspergillosis requires animal models that are reproducible among different laboratories. We therefore evaluated a murine model of aerosol infection in two independent laboratories and found a high level of both intra- and interlaboratory reproducibility of survival, fungal burden over time, and the efficacy of liposomal amphotericin B.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17005844      PMCID： PMC1610079          DOI： 10.1128/AAC.00787-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Value of an inhalational model of invasive aspergillosis.

Authors:  William J Steinbach; Daniel K Benjamin; Scott A Trasi; Jackie L Miller; Wiley A Schell; Aimee K Zaas; W Michael Foster; John R Perfect
Journal:  Med Mycol       Date:  2004-10       Impact factor: 4.076

2.  The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy.

Authors:  Shane D Stephens-Romero; Aron J Mednick; Marta Feldmesser
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis.

Authors:  D C Sheppard; K A Marr; D N Fredricks; L Y Chiang; T Doedt; S G Filler
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067

4.  Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate.

Authors:  J C Bowman; G K Abruzzo; J W Anderson; A M Flattery; C J Gill; V B Pikounis; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Novel inhalational murine model of invasive pulmonary aspergillosis.

Authors:  Donald C Sheppard; Gunter Rieg; Lisa Y Chiang; Scott G Filler; John E Edwards; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

6.  Efficacy of oral saperconazole in systemic murine aspergillosis.

Authors:  L H Hanson; K V Clemons; D W Denning; D A Stevens
Journal:  J Med Vet Mycol       Date:  1995 Sep-Oct

7.  Experimental study of the pathogenicity of aspergilli for mice.

Authors:  S Ford; L Friedman
Journal:  J Bacteriol       Date:  1967-10       Impact factor: 3.490

8.  Immunologic studies of disseminated infection with Aspergillus fumigatus in the nude mouse.

Authors:  D M Williams; M H Weiner; D J Drutz
Journal:  J Infect Dis       Date:  1981-05       Impact factor: 5.226

9.  Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.

Authors:  Laura K Najvar; Anthony Cacciapuoti; Steve Hernandez; Judith Halpern; Rosie Bocanegra; Maya Gurnani; Frederick Menzel; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

10.  Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals.

Authors:  Roberta Gaziano; Silvia Bozza; Silvia Bellocchio; Katia Perruccio; Claudia Montagnoli; Lucia Pitzurra; Giovanni Salvatori; Rita De Santis; Paolo Carminati; Alberto Mantovani; Luigina Romani
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191
View more
  26 in total

1.  Mouse models for the study of fungal pneumonia: a collection of detailed experimental protocols for the study of Coccidioides, Cryptococcus, Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus.

Authors:  Maged Muhammed; Marta Feldmesser; Lisa F Shubitz; Michail S Lionakis; Anita Sil; Yan Wang; Justin Glavis-Bloom; Russell E Lewis; John N Galgiani; Arturo Casadevall; Dimitrios P Kontoyiannis; Eleftherios Mylonakis
Journal:  Virulence       Date:  2012-05-01       Impact factor: 5.882

2.  Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.

Authors:  Justin A Tolman; Nathan P Wiederhold; Jason T McConville; Laura K Najvar; Rosie Bocanegra; Jay I Peters; Jacqueline J Coalson; John R Graybill; Thomas F Patterson; Robert O Williams
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

3.  A transcriptional signature accurately identifies Aspergillus Infection across healthy and immunosuppressed states.

Authors:  Julie M Steinbrink; Aimee K Zaas; Marisol Betancourt; Jennifer L Modliszewski; David L Corcoran; Micah T McClain
Journal:  Transl Res       Date:  2020-02-20       Impact factor: 7.012

Review 4.  Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection.

Authors:  I Mirkov; S Stosic-Grujicic; M Kataranovski
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

5.  Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Laura K Najvar; Satoru Matsumoto; Rosie A Bocanegra; Monica L Herrera; Brian L Wickes; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

6.  Cutaneous model of invasive aspergillosis.

Authors:  Ronen Ben-Ami; Russell E Lewis; Konstantinos Leventakos; Jean-Paul Latgé; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

7.  Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Authors:  Julien P Maincent; Laura K Najvar; William R Kirkpatrick; Siyuan Huang; Thomas F Patterson; Nathan P Wiederhold; Jay I Peters; Robert O Williams
Journal:  Drug Dev Ind Pharm       Date:  2016-10-05       Impact factor: 3.225

8.  Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.

Authors:  Célimène Galiger; Matthias Brock; Grégory Jouvion; Amélie Savers; Marianna Parlato; Oumaïma Ibrahim-Granet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

9.  Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.

Authors:  Ana C Vallor; William R Kirkpatrick; Laura K Najvar; Rosie Bocanegra; Marsha C Kinney; Annette W Fothergill; Monica L Herrera; Brian L Wickes; John R Graybill; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

10.  Strain-dependent variation in 18S ribosomal DNA Copy numbers in Aspergillus fumigatus.

Authors:  M L Herrera; A C Vallor; J A Gelfond; T F Patterson; B L Wickes
Journal:  J Clin Microbiol       Date:  2009-03-04       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.